# Bronchogen

> Bronchogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed within the Russian 'bioregulator' peptide research tradition associated with the St. Petersburg Institute of Bioregulation and Gerontology. It is promoted as a tissue-specific regulator intended to support bronchial and respiratory tissue function, and is primarily marketed and studied in Russia and neighboring countries rather than through Western regulatory pathways. Independent, large-scale clinical trial data outside this research group are limited, so claims about its effects should be treated as preliminary and unverified by major regulatory agencies such as the FDA or EMA. It is not an approved prescription drug in the United States or European Union and is best regarded as an emerging research compound.

- URL: https://www.lifeconverted.com/peptides/bronchogen
- Primary category: Other & Clinical
- Effectiveness rank: #26 in Other & Clinical
- Evidence level: Emerging research
- Route: Subcutaneous (Original research used subcutaneous injection; commercial products are more commonly sold as oral capsules, which have different absorption characteristics.)
- Dose range: 50-200 mcg
- Dose tiers: low 50 mcg; moderate 100 mcg; high 200 mcg
- Half-life: Not well characterized; expected to be extremely short (on the order of minutes) given rapid proteolytic degradation typical of small, unprotected peptides
- Timing: Morning
- Cycle: Reported as a short course of about 10 days in published bioregulator protocols on, Several months between courses, with courses sometimes repeated once or twice per year off (Based on Russian bioregulator peptide dosing conventions; these protocols have not been independently validated in large Western clinical trials.)
- Storage: Refrigerate at 2-8°C, protected from light; use reconstituted material promptly.

## Mechanism of action

Consistent with the proposed model for other short bioregulator peptides in this research line, Bronchogen is theorized to interact with gene regulatory regions to influence protein synthesis in bronchial and respiratory epithelial tissue, potentially supporting normal cellular turnover and function. As a short, unmodified tetrapeptide, it is expected to be rapidly degraded by peptidases once administered, and the precise molecular target and pharmacodynamics have not been established through independent, mechanistic studies.

## Reported benefits

- Proposed support for bronchial and respiratory tissue function in preliminary Russian research
- Represents a short, simple peptide structure suggested to have a favorable safety profile in publications from its developers
- Used in some Eastern European clinical settings as an adjunct for respiratory conditions

## Reported side effects

- Limited independent safety data outside the originating research group
- Potential injection site reactions with parenteral use
- Theoretical risk of allergic response, as with any peptide product
- Effects and risks with long-term or repeated use are not well characterized

## Common protocols

- 10-day course as part of Khavinson-style bioregulator peptide protocols for respiratory tissue support, primarily used and marketed in Russia and neighboring countries

## Stacking notes

Sometimes combined with other tissue-specific bioregulator peptides from the same research line in published protocols; evidence supporting any additive benefit from combination is limited.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer